Carlyle-backed life sciences investor launches $1.5bn clinical trials fund
Stay informed with free updates Simply sign up to the US & Canadian companies myFT Digest — delivered directly to your inbox. Carlyle-backed investor Abingworth is tapping investors for a fund worth up to $1.5bn to bankroll clinical trials, as it pioneers partnerships with big pharmaceutical companies for a share of royalties from new drugs….